A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control

GnRH antagonist and GnRH agonist are widely used as androgen deprivation therapy for metastatic prostate cancer. A previous report demonstrated that patients with PSA levels of >20 ng/mL using GnRH antagonists showed favorable outcomes in comparison to those using GnRH agonists. An 82-year...

Full description

Bibliographic Details
Main Authors: Rumiko Sugimura, Takashi Kawahara, Yasuhide Miyoshi, Masahiro Yao, Sawako Chiba, Hiroji Uemura
Format: Article
Published: Karger Publishers 2019-09-01
Series:Case Reports in Oncology
Online Access:https://www.karger.com/Article/FullText/502859